Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners.
Medical advances depend on the participation of patients in clinical studies. We are grateful to all participants in our clinical trials, their friends and families, who make a positive contribution towards a better future for all people living with severe diseases.
Learn more about our currently recruiting clinical trials below.
Pfizer is conducting a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male participants with moderately severe or severe hemophilia A.
Sanofi is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and efficacy of SAR445136 ex vivo cell therapy in severe sickle cell disease.
We are conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.
A Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ST-400 ex vivo cell therapy in transfusion-dependent beta thalassemia is ongoing and no longer recruiting.
A Phase 1/2 clinical trial evaluating the safety, tolerability, and time-course profile of FVIII activity levels of SB-525/giroctocogene fitelparvovec gene therapy in hemophilia A is ongoing and no longer recruiting.